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Abstract Polymer, lipid, metal, semiconductor, and hybrid composite 
nanoparticles with dimensions < 100 nm, have been developed extensively 
for potential biomedical applications like drug delivery systems, molecular 
sensing devices, and diagnostic imaging. In this overview, only inorganic 
nanoparticles for drug delivery will be addressed. Inorganic nanoparticles 
exhibit magnetic, electrical and optical properties that differed from their 
bulk counterparts. These physical properties could be tailored by controlling 
the size, shape, surface, and domain interactions in the nanoparticles. The 
incorporation of the unique properties of nanoparticles has expanded alternative 
platforms for drug delivery. The drug delivery systems highlighted in this 
overview include unguided, magnetically-guided, and optically-triggered 
delivery systems. These delivery systems are developed to enable improved 
localization and control of the drug’s sphere of influence. This would potentially 
allow for more efficient therapy with lower dosages and reduced adverse 
side effects. 
11.1 Introduction
Nanoparticles have driven the development of various biomedical applications, 
including drug delivery systems, diagnostic imaging, and molecular sensing devices 
(Jaspreet et al., 2005; West and Halas, 2000, 2003; Prasad, 2004; Holm et al., 2002). 
In this overview, only inorganic nanoparticles for drug delivery are addressed. 
Sustained release and targeted drug delivery systems are designed to optimize 
therapeutic efficiency of drugs and localize the drug’s sphere of influence to 
regions of interest (Jaspreet et al., 2005; Brannon-Peppas and Blanchette, 2004; 
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Kost and Langer, 2001). The optimal drug delivery system must not be removed 
too rapidly from either the systemic circulatory system or region of interest, and 
maintain a minimal drug leakage away from target site. Drugs released from the 
carriers should remain functionally active, and unloaded drug carriers should 
subsequently be cleared from systemic circulation (Petrak, 2006). 
The characteristic dimensions of nanoparticles in the length scale of < 100 nm 
have driven interests for its applications in intravenous delivery, pulmonary 
delivery, and intracellular delivery. Using nanoparticles, an improved efficiency 
for pulmonary delivery was achieved (Chavanpatil et al., 2006; Hughes, 2005). 
For applications of nanoparticles in cancer therapy, liposomes and polymeric 
drug carriers of  100 nm were reported to show increased permeability and 
localization at tumor sites. This was attributed to reduced diffusive barrier for 
nanoparticles given that gap junctions of the tumor vasculature were estimated to 
be ~100 600 nm (Allen, 2002; Panyam and Labhasetwar, 2003). Besides 
particle size, surface properties of nanoparticles would influence cellular uptake 
and distribution of nanoparticles (Moghimi et al., 2001). Nanoparticles with a 
more hydrophobic surface are taken up by cells to a greater extent through both 
endocytosis and phagocytosis than those with a hydrophilic surface. 
Surface modification of nanoparticles is often required to improve its stability, 
compatibility, and functionality. Surface characteristics of nanoparticles have been 
engineered using surfactants that served as molecular linkers and improved 
particle stability (Kossovsky et al., 1994; Love et al., 2005; Caruso, 2002; Chan, 
2006). Surfactants would reduce the surface energy of nanoparticles and enhance 
its stability by acting as a barrier to agglomeration through either steric hindrance 
or repulsive electrostatic forces. Functional groups on surfactants have enabled 
the coupling of nanoparticles with biomolecules such as drugs or antibodies (see 
Fig. 11.1). Subsequently, the surface functionalized nanoparticles would be able 
to serve as drug carriers, with potential for specific localization if particles were 
also modified with antibodies. 
Figure 11.1  Schematic of surface functionalization of inorganic nanoparticles 
Ceramics such as calcium phosphates (e.g. hydroxyapatite), silica, and titania 
are known to be biocompatible (Jin and Ye, 2007). The use of inorganic ceramic 
nanoparticles offers higher thermal and chemical stability than polymeric 
nanoparticles. Thus, encapsulation of drugs within ceramic particles would give 
better protection of labile agents against denaturation (Hasirci et al., 2006). In 
addition, with the increasing percentage of surface atoms and increasing separation 
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between energy states (i.e. more discrete energy levels) with decreasing size, 
inorganic nanoparticles exhibit unique magnetic, electrical and optical properties 
that differ from its bulk counterparts (Kittel, 2005; Whitesides, 2005; Pitkethly, 
2004). Properties of nanoparticles could be tailored by controlling the size, 
crystal structure, shape, surface, and domain interactions in nanoparticles. For 
instance, Au nanoparticles of 5 nm and bulk Au did not exhibit any absorption 
within the visible range, while Au nanoparticles with diameters of 5 100 nm 
showed a distinct size-dependent absorption band at 520 570 nm (Kreibig and 
Vollmer, 1995; Link and El-Sayed, 1999, 2000). In addition, optical properties of 
metallic nanoparticles could be modified by using different surfactants to tailor 
optical properties (Persson, 1993; Linnert et al., 1993; Hilger et al., 2000; 
Salgueiriño-Maceira et al., 2003; Pinchuk et al., 2004). Therefore, physical 
properties of inorganic nanoparticles could be exploited to enable local release at 
regions of interest with tunable sensitivity and responsiveness. Drug-loaded 
magnetic nanoparticles could be guided under an applied magnetic field to a 
specific area for subsequent release. Similarly, localized release could be 
achieved using light to trigger drug release from optically-active drug 
nanocarriers.
The drug delivery systems highlighted in this overview are unguided, magnetically- 
guided and optically-triggered delivery systems. An introduction to the different 
approaches adopted by each drug delivery system will be described. An overview 
of different chemical synthetic and surface functionalization methods for the 
different carriers are also presented. Besides some commonly used ceramic 
nanoparticles like hydroxyapatite, considering that most inorganic nanoparticles 
are non-resorbable and non-degradable with unknown in vivo clearance, significant 
nanoparticle accumulation within the systemic circulation may occur (Singh et al., 
2006). With the increasing dominance of size and surface effects at the nanoscale, 
toxicity assessments of conventional bulk materials (U.S. Food and Drug 
Administration, 2000) and microparticles (Foster et al., 2001) may not be 
applicable. Thus, it would be crucial to evaluate cytotoxic effects of nanoparticles 
(Hood, 2004; Kagan et al., 2005; Barnard, 2006; Sayes et al., 2004; Kirchner et 
al., 2005). Cytotoxic properties of non-degradable magnetic and optically-active 
inorganic nanoparticles would be mentioned in this chapter.  
11.2  Unguided Drug Delivery Systems  
Ceramic nanoparticles have mostly been developed for sustained drug release 
systems to enhance delivery efficiency, reduce undesired systemic effects and 
improved convenience to patients. The most popular ceramic materials used in 
clinical applications are silica and calcium phosphate (e.g. hydroxyapatite). Besides 
non-viral gene delivery, their most significant contribution was found as substrates 
for tissue engineering, bone regeneration and bone repair (Vallet-Regi, 2006). In 
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particular, calcium-based ceramic materials have an advantage over other 
polymeric materials for bone repair due to its better bonding to living bone and 
its ability to catalyze bone growth due to increased nucleation of apatite. For 
instance, hydroxyapatite is a ceramic similar to the mineral part of bone. 
Biomolecules and therapeutic agents were combined with ceramic particles to 
develop materials that functioned as controlled release systems (Vallet-Regi, 
2006; Gadre and Gouma, 2006). Performance of biodoped ceramics were governed 
by the chemical activity and functionality of attached biomolecules. Adsorption 
properties of ceramic materials are governed partly by pore size, matrix structure, 
and surface functional groups. Surface functional groups could be further 
modified using different chemical species to expand its ability to attach different 
biomolecules. The chemical activity of biomolecules would be influenced by 
interfacial interactions between biomolecules and ceramic matrix. An ideal 
biodoped ceramic would exhibit a good long term stability under potentially 
adverse conditions, high loading density for biomolecules that remains bioactive, 
and resistant to leaching of biomolecules (Vallet-Regi, 2006). Biodoped ceramic 
materials have been used either as a porous solid piece (e.g. implants) or in 
injectable form for development of non-invasive surgical applications (Vallet-Regi, 
2006; Ben-Nissan, 2004; Hou et al., 2004; Temenoff and Mikos, 2000). 
11.2.1  Chemical Synthesis of Ceramic Nanomaterials 
Main chemical synthetic methods for ceramics include sol-gel processing and 
precipitation. The sol-gel technique typically involved hydrolysis of metal alkoxide, 
M(OR)x precursors in the presence of alcohol as a co-solvent to form metal 
hydroxyls (Klein, 1996; Livage et al., 1998; Vioux, 1997; Oskam, 2006; Brinker 
and Sherrer, 1990; Niederberger and Garnweitner, 2006). This was followed by 
condensation of metal hydroxyl groups, where either water or alcohol as by 
product. Some processing parameters commonly used to control nucleation and 
growth kinetics were chain length of metal alkoxide precursors, surfactants, 
solvent (molecular weight of alcohol), temperature, pH, and mechanical agitation. 
As condensation continues, larger aggregates were formed and viscosity of sol 
increases resulting in subsequent formation of a gel. Capillary forces during 
solvent removal from the pores would lead to gel shrinkage. Using the Stöber 
method developed from sol-gel principles, silica particles with a range of different 
sizes was prepared (Green et al., 2003). Another common method, particularly 
for hydroxyapatite, is precipitation of metallic salt (calcium nitrates) with a base 
(ammonium phosphate) (Ahn et al., 2001; Kumta et al, 2005). The nucleation 
and growth kinetics were primarily governed by the pH of the starting solution 
(Ahn et al., 2001; Kumta et al., 2005). The degree of crystallization and 
prevention of growth of undesired secondary phases were controlled by using 
different aging temperatures. 
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11.2.2  Functionalization of Ceramic Nanomaterials 
Silica nanoparticles without surface modification did not seem to condense and 
deliver DNA (Luo and Saltzman, 2006). For DNA delivery using nanoparticles, 
the extended long chain DNA molecules were condensed to reduce its occupied 
spatial volume. The presence of surface amino groups on silica nanoparticles upon 
modification with aminosilanes, would enable it to tightly bind with plasmid 
DNA and serve as a gene delivery carrier. Using silica nanoparticles as a gene 
delivery carrier would prevent DNA from being degraded by environmental 
enzymes. In addition, it was reported that DNA-loaded silica nanoparticles 
showed an enhanced cellular uptake when compared to other commercial DNA 
transfection vectors available. Silica nanoparticles were found to enhance the 
transfer efficiency of commercially available transfection vectors by a factor of  
1 7 (Luo, 2005; Xu et al., 2006). Another commonly used non-viral gene 
delivery carrier is calcium phosphate (apatite, hydroxyapatite, and carbonated 
apatite) based materials. Calcium phosphate materials are suitable candidates as a 
gene delivery carrier due to its biocompatibility, biodegradability and known 
adsorptive capacity of DNA on bare calcium phosphate. Calcium phosphate gene 
carriers were prepared through the co-precipiation of calcium phosphate particles 
with DNA (Luo, 2005; Olton et al., 2007; Zhu et al., 2004). However, lower levels 
of gene expression in comparison to viral approaches were observed. This was 
associated with difficulties associated with endosomal escape, insufficient protection 
of DNA from nuclease degradation, and inefficient nuclear uptake. 
Biomolecules were often encapsulated using a modified sol gel process with 
addition of amino acids, sugars, or cytoprotecting agents like glycerol or other 
polymer additives like polyethylene glycol (Avnir et al., 2006; Coradin and Livage, 
2007). Protein encapsulation within rigid ceramic pores of similar dimensions 
offers protection against other denaturing forces in the presence of an organic 
solvent or extreme pH. Porous blocks of calcium hydroxyapatite and tricalcium 
phosphate were evaluated as sustained release system fro anticancer drugs, 
cisplatin, and methotrexate (Uchida et al., 1992; Itokazu et al., 1998). In addition, 
hybrids of ceramic and polymeric materials mixed with therapeutic agents (e.g. 
tissue growth factors or small molecule drugs) are often used. Polymeric-ceramic 
hybrids offer a combination of properties that were unique to either polymeric or 
ceramic materials alone. Properties of such polymeric-ceramic hybrids would 
depend on the percentage of each constitutive component present. A sustained 
release strategy developed was the use of a polymer (poly(lactic-co-glycolic acid)) 
with acidic degradation products to control the dissolution of a basic inorganic 
component (apatite) on which a therapeutic agent (e.g. bone morphogenetic 
proteins) were adsorbed (Yong et al., 2004; Yong, 2005). The release profile 
could be altered by changing variables that affect polymer degradation (type, 
molecular,and composition) and/or apatite dissolution (loading and particle size). 
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11.3  Magnetically-Guided Drug Delivery Systems 
11.3.1  Magnetic Guiding 
Magnetically-responsive delivery systems introduced into the systemic circulation 
are directed to regions of interest using an applied magnetic field. The external 
magnetic field of ~0.8 1.7 T, may be a magnet or an array of magnets placed 
near a lesion or tumor, either externally placed or implanted. (Hayden and Häfeli, 
2006; Gould, 2006; Alexiou et al., 2006; Jurgons et al., 2006). Therapeutic agents 
were subsequently released using either another trigger such as ultrasonic waves 
or an alternating magnetic field (Kost and Langer, 2001; Tirelli, 2006; Frimpong 
et al., 2007). Magnetically modulated drug delivery systems prepared using large 
magnetic particles embedded in a polymer matrix, were shown to enhance drug 
release rates upon application of an oscillating magnetic field. Drug release rates 
were shown to be dependent on the characteristics of magnetic field (e.g. field 
strength, and amplitude) and polymer properties (e.g. rigidity of polymer matrix). 
When the holding magnets were removed, the particles would either redistribute 
into the blood supply to be eventually cleared by the reticuloendothelial system 
or remain within the region of interest to be cleared by extravasation. 
Recent studies demonstrated successful localization of doxorubicin-loaded 
200 nm Fe@C particles, and 80 nm to 2 m silica-coated Fe3O4/ -Fe2O3 particles 
using implanted Au-plated permanent magnets. The magnetic implants were 
Au-plated to improve chemical stability and biocompatibility. Though high particle 
concentrations were found in the liver, magnetic carriers were drawn to the left 
kidney close to an implanted magnet whereas no particles were observed in right 
kidneys of the rabbits tested. Similar studies using externally placed magnets 
showed successful localization of magnetic particles at the peritoneal cavity of 
mice. The efficacy and potential for pulmonary embolism of magnetically-guided 
drug delivery systems would be governed by physiological parameters, temporal 
localization kinetics, and microcirculatory flow (Lübbe et al., 1999). 
11.3.2  Chemical Synthesis and Properties of Magnetic  
Nanostructures
Iron-based magnetic nanomaterials, particularly magnetite (Fe3O4) or maghemite 
( -Fe2O3) due to its better chemical stability and lower toxicity, are most commonly 
used compared to alternative cobalt- and nickel- based nanomaterials (Qiang et 
al., 2006). Magnetic nanoparticles have been prepared using several chemical 
methods to control nucleation and growth rates. The size, morphology, and 
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composition of particles synthesized were governed by the nucleation and growth 
rates, whereas the size dispersion would depend on decoupling of nucleation and 
growth rates (Turkevich et al., 1951; Stokes and Evans, 1997; Sheludko, 1996; 
Davey and Garside, 2000; Huber, 2005). Base precipitation of iron salts from a 
surfactant-containing aqueous solution at low temperatures was a common 
chemical method for aqueous synthesis of magnetic nanoparticles (Chatterjee et 
al., 2003). Another synthetic method is the thermal decomposition of organometallic 
precursors in high-boiling solvents in the presence of stabilizing ligands, such as 
oleic acid or oleyl amine. Organometallic-based synthesis often resulted in magnetic 
nanoparticles with a narrow size distribution (  < 5%) and high degree of 
crystallinity (see Fig. 11.2) (Lin and Samia, 2006; Park et al., 2004; Behrens et 
al., 2006; Hyeon, 2003). 
Figure 11.2  (a) 7 nm (b) 11 nm and (c) 13 nm -Fe2O3 nanoparticles synthesized 
using thermal decomposition of organometallic precursors (Hyeon, 2003; Hyeon et 
al., 2001). Adapted from (Hyeon, 2003). Reprinted with permission from (Hyeon 
et al., J. Am. Chem. Soc. 2001). Copyright (2001) American Chemical Society 
The magnetic particles must exhibit high magnetization and superparamagnetic 
behavior at room temperature for guidance and immobilization to region of 
interest (Neuberger et al., 2005). Particles with high saturation magnetization 
would be localized more easily to a region using lower external magnetic fields. 
As the size decreases, thermal energy may be sufficient to give rise to fluctuations 
of magnetization directions. Thus, particles below a critical size (e.g. ~10 nm for 
Fe3O4 or -Fe2O3) would be magnetized by an applied magnetic field but retain 
no permanent magnetism upon removal of the applied field. Particles with this 
superparamagnetic behavior would have reduced tendency for agglomeration that 
was driven by magnetic attractive forces. While decreasing particle size would 
result in the desirable superparamagnetic behavior, a trade-off would be reduced 
saturation magnetization. Smaller particles with lower saturation magnetization 
may have less effective localization, while larger particles may have lower cellular 
uptake and higher chances for embolism. 
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11.3.3  Functionalization of Magnetic Nanoparticles 
Surfaces of magnetic nanoparticles are modified with polymeric, metallic or 
oxide surface to improve either its stability against agglomeration, bioavailability 
and biomolecular functionalization (A.K. Gupa and M. Gupa, 2005; Berry and 
Gurtis, 2003). Particles were often surface functionalized with either an organic, 
polymeric or inorganic layer using either ligand exchange or encapsulation methods 
(Hong et al., 2005; Bruce and Sen, 2005; Templeton et al., 2000). Particles were 
coated with a layer of organic surfactants during chemical synthesis to prevent 
agglomeration. However, such surfactants might not provide the necessary 
chemical functionality needed for its eventual applications. Thus, surfactants 
covering the particles were replaced with other surfactants using various ligand 
exchange methods. Particles could be encapsulated by a polymeric coating by 
precipitation of inorganic salts in an aqueous polymer solution (Yu and Chow, 
2004; Babes et al., 1999). For instance, Fe3O4 or -Fe2O3 particles were 
commonly encapsulated with dextran or starch for improved biocompatibility 
and solubility. It was also demonstrated that after surface modification, an 
anticancer drug (carboplatin) was bound to polymethyl metacrylic acid coated 
-Fe2O3 particles (Fig. 11.3) (Yu and Chow, 2004). Silica-coated particles provide 
enhanced stability and surface silanol groups for covalent coupling (Bruce and 
Sen, 2005). After hydrolysis and condensation of organosilanes that were 
deposited on the particle surface, a silica coating was formed. Characteristics of 
the final surface layer depended on reaction variables such as solvent type, 
temperature, or time, as well as on the catalyst and organosilane concentrations 
used.
Figure 11.3  Transmission electron micrograph and corresponding electron diffraction 
pattern of polymethyl acrylic acid coated -Fe2O3 particles (Yu and Chow, 2004). 
—Reproduced by permission of The Royal Society of Chemistry 
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11.3.4  Biocompatibility of Magnetic Nanoparticles for Drug Delivery 
It was reported that besides intrinsic size effects, the surface coating had an 
important role in the cytotoxicity of oleic acid coated nickel ferrite nanoparticles 
(Yin et al., 2005). It was found that particle size of uncoated nickel ferrite was not a 
significant factor on cytotoxicity when there were no ‘toxic’ functional groups on 
particle surface. In contrast, oleic acid-coated nickel ferrite particles of ~150 nm 
and ~10 nm were cytotoxic. If oleic acid molecules were present as monomer, 
they were not cytotoxic. However, if they developed micelles or coated on the 
ferrite particles, i.e. when their functional groups were spatially aligned, cytotoxicity 
was observed. Larger particles had a larger cytotoxic effect than smaller particles 
when one or two layers of oleic acid were deposited on particle surface. This 
could be related to surfactant reactivity and interfacial interaction areas that were 
dependent on particle size. The difference in surface energies with particle sizes 
may have affected surfactant conformation, which may alter the surfactant reactivity. 
Thus, the same surfactant may behave differently when it interacts with cells. 
Also, with a larger effective interaction area for a larger particle compared to that 
for a smaller particle as shown in Fig. 11.4, the larger particle will exert a larger 
localized stimulus on the cells. It was subsequently suggested in the report that 
that a single localized stimulus from a larger particle was stronger and more toxic 
than an equivalent sum of stimuli at different locations exerted by smaller particles. 
Figure 11.4  Sketch of the various interaction areas of individual particle with one 
layer oleic acid coating. A single large particle possessed larger interaction areas 
with more function groups. While, the big number of small particles increased 
number of interaction points, there were less functional groups at each interaction 
point (Yin et al., 2005). —Reprinted from H. Yin, H.P. Too and G.M. Chow. The 
effects of particle size and surface coating on the cytotoxicity of nickel ferrite. 
Biomaterials, 26: 5818 5826, Copyright (2005), with permission from Elsevier 
11.4  Optically-Triggered Drug Delivery Systems 
Near infrared (NIR) light ( 650 1000 nm), with its deep penetration in living 
tissues shown in and high signal-to-background ratio, has been exploited for 
biomedical imaging, photoablation and photodynamic therapy (Frangioni, 2003; 
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Sato et al., 2001; Dolmans et al., 2003). The extent of NIR light propagation 
would be governed by absorption and scattering properties of tissues (Waynant et 
al., 2001; Niemz, 2002; Vogel and Venugopalan, 2003). Major tissue absorbers of 
NIR light are hemoglobin, melanin, and water, while composition, size, and 
morphology of tissue components control the light scattering. The absorption and 
scattering properties would influence volumetric energy distribution induced by 
laser irradiation, and set the boundaries for localized NIR-activated drug release 
systems. NIR light was reported to travel through 10 cm of breast tissue and 4 cm 
of skull tissue using microwatt sources (Weissleder, 2001). A targeted drug delivery 
system that incorporated NIR-sensitive nanoparticles and tissue penetrative NIR 
light to trigger drug release was developed (Ren and Chow, 2003; Chow et al., 
2006; Tan, 2006). This could potentially improve chemotherapy treatment by 
minimizing deleterious side effects and allowing minimally invasive treatment of 
surgically inoperable tumors. 
11.4.1  Chemical Synthesis and Properties of NIR-Sensitive  
Nanoparticles
Metallic nanoparticles and metallic nanoshells with size-dependent optical properties, 
particularly chemically stable Au nanoparticles, have been utilized as molecular 
sensors (West and Halas, 2003; Prasad, 2004; Holm et al., 2002). As sensors, binding 
of molecules would give rise to either fluorescence enhancement or plasmon 
resonance shifts. NIR-sensitive metallic nanoshells (Oldenburg et al., 1998). with 
size and shell thickness dependent properties were investigated for applications 
in imaging (Loo et al., 2005), hyperthermia (Hirsch et al., 2003), temperature- 
responsive delivery systems (Sershen and West, 2006), and immunoassays (Hirsch 
et al., 2003, 2006). For the NIR-activated drug delivery system, the NIR-sensitive 
nanoparticles were synthesized by reduction of HAuCl4 with Na2S (Ren and 
Chow, 2003; Chow et al., 2006; Zhou et al., 1994; Averitt et al., 1997). These 
as-synthesized nanoparticles were chemically stable and exhibited two absorption 
bands at ~530 nm and in the NIR region of 650 1100 nm. The as-synthesized 
nanoparticles were composites of crystalline Au and amorphous Au2S (Tan, 2006; 
Tan et al., Submitted). The NIR absorption was unique to as-synthesized 
nanoparticles, and was absent in either Au or Au2S nanoparticles. There was no 
evidence that NIR absorption properties were related to a core-shell structure as 
suggested in earlier work in the literature. Therefore, NIR absorption was likely 
due to interfacial effects on particle polarization from introduction of amorphous 
Au2S in a predominantly crystalline Au matrix (Tan, 2006; Tan et al., Submitted). 
The effects of concentration ratios for precursors used in the chemical synthesis of 
nanoparticles were correlated with the resultant NIR properties. Consequently, by 
varying concentration ratios of precursors, the optical properties of as-synthesized 
nanoparticles were tailored (Chow et al., 2006; Tan, 2006). This ability to tailor 
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optical properties would advance potential use of as-synthesized nanoparticles 
for optically-activated drug delivery systems or other biomedical applications. 
11.4.2  Functionalization of NIR-Sensitive Nanoparticles 
Functionalization of NIR-sensitive Au-Au2S nanoparticles with surfactants has 
facilitated the loading of anticancer drugs as shown in Fig. 11.5 (Chow et al., 
2006; Tan, 2006). Surfactants of different hydrocarbon chain lengths were used 
to modify the nanoparticles, and subsequently altered interfacial interactions 
between nanoparticles and surfactants. The loading of anticancer drugs governed 
by surfactant interfacial interactions was correlated to the surfactant chain length. 
In addition, inorganic-organic interfacial interactions between nanoparticles and 
surfactants may be used to manipulate the optical properties of NIR sensitive drug 
delivery system. Drug release was triggered upon NIR laser irradiation using a 
Nd:YAG pulse laser at 1064 nm (Ren and Chow, 2003). The structural and 
microstructural changes of Au-Au2S nanoparticles upon NIR laser irradiation 
were studied. Insights to NIR triggered drug release process were elucidated 
from the estimated magnitude of thermal effects and structural and microstructural 
changes induced by NIR irradiation (Tan, 2006). 
Figure 11.5  Cisplatin-loaded surface modified Au-Au2S nanoparticles (Ren and 
Chow, 2003).—Reprinted from L. Ren and G.M. Chow. Synthesis of NIR-sensitive 
Au-Au2S nanocolloids for drug delivery. Materials Science and Engineering C, 23: 
113 116, Copyright (2003), with permission from Elsevier 
11.4.3  Biocompatibility of NIR-Sensitive Nanoparticles for Drug  
Delivery
The in vitro cytotoxicity of the NIR-sensitive Au-Au2S drug delivery system was 
assessed using breast cancer cells for its potential clinical application (Tan, 2006). 
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The in vitro cytotoxicity of surfactant-modified nanoparticles and drug-loaded- 
surfactant-modified nanoparticles were investigated. (Tan, 2006) It was found 
that the in vitro toxicity of drug-loaded-surfactant-modified nanoparticles depended 
on the surfactant used for drug adsorption. The in vitro cytotoxic effects of 
released drugs in the supernatant fraction collected after NIR irradiation of 
drug-loaded-surfactant-modified nanoparticles were evaluated. It was found that 
the released drug was chemically modified with increased toxicity. In addition, 
transmission electron microscopy (TEM) micrographs indicated that both Au-Au2S
nanoparticles and cisplatin-loaded Au-Au2S nanoparticles were found associated 
with the plasma membrane or in small vesicles within cells. Studies on in vitro 
carcinogenicity of nanoparticles using a medium-term (25 days) NIH/3T3 cells 
transformation test was also conducted (Ren et al., submitted). Examination 
using light microscopy of the cells exposed to the Au-Au2S NPs and cisplatin- 
loaded Au-Au2S nanoparticles revealed morphological alterations when compared 
to that of control cells. However, no difference in cell morphology among cells 
exposed to cisplatin-loaded Au-Au2S nanoparticles was observed. This indicated 
that cisplatin-loaded Au-Au2S nanoparticles did not cause carcinogenicity in vitro 
below a maximum recommended dosage in the given system. 
Similar in vivo biodistribution profiles (Fig. 11.6) of nanoparticles using both 
intra-tumor and tail vein injection administration routes were observed (Huang et 
al., submitted). Most particles accumulated in the reticulo-endothelial system, 
mainly liver and spleen. Small amounts of Au-Au2S nanoparticles were found in 
the lung, probably due to embolism of agglomerated nanoparticles in lung 
capillaries. While the mass of Au-Au2S NPs in the kidneys increased to 0.95 g/g 
within 7 days, no Au-Au2S NPs were deposited in other organs like brain, heart, 
muscle, bone, intestine, and blood. Using the tail vein injection for particle 
administration resulted in reduced concentration in the biodistribution profile  
Figure 11.6  Biodistribution of Au-Au2S NPs in KM mice treated by intra-tumor 
injection at different time points (Huang et al., submitted) 
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compared to that of using the intra-tumor route. This was due to the enhanced 
penetration and retention effect of tumors for particles of 50 100 nm. This 
suggested that intra- tumor injection may improve local tumor response and 
minimize any systemic side effects. 
In summary, preliminary findings from the short and long-term in vitro 
suggested that cisplatin-loaded Au-Au2S nanoparticles were non-toxic below a 
maximum recommended dosage. It remains premature to draw definitive 
conclusions about the toxicities, if any, of Au-Au2S nanoparticles. Further work 
is required to evaluate if the unique physicochemical properties of Au-Au2S
nanoparticles would introduce other injurious mechanisms and pathological lesions. 
11.5  Summary 
The incorporation of the unique properties (chemical stability, magnetic and optical) 
of inorganic nanoparticles has expanded alternative platforms for drug delivery. 
These drug delivery systems were developed to enable improved localization and 
control of the drug’s sphere of influence. This would potentially allow for more 
efficient therapy with lower dosages and reduced adverse side effects. A 
multidisciplinary approach would be needed for advancement of the delivery 
systems to its eventual applications. Optimization of chemical synthetic and 
functionalization methods to improve quality (distribution, loading capacities) of 
drug carrier would facilitate developmental progress of drug delivery systems. 
Further scientific development on understanding of release mechanisms for better 
engineering control of these drug delivery systems would be required. More detailed 
in vitro and in vivo work on the nanoparticle-cellular interfacial interactions and 
its implications on safety of inorganic nanoparticles would also be critical. 
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